By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GENFIT Corp. 

245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405


SEARCH JOBS
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001


Key Statistics


Email: Karen.Miller@Genfit.com
Ownership: Public

Web Site: GENFIT Corp.
Employees: 125 (Scientists: 100)
Symbol: ALGFT
 









Company News
GENFIT Corp. (ALGFT)To Participate In Four Upcoming Investor Events 8/26/2014 2:46:07 PM
GENFIT Corp. (ALGFT) Release: Minutes Of The Annual General Meeting Of June 20, 2014 6/23/2014 9:06:27 AM
GENFIT Corp. (ALGFT): Organization Of A Workshop On GFT505 During The Annual EASL Congress 4/8/2014 2:28:00 PM
GENFIT Corp. (ALGFT): Preclinical Data Support Anti-Cancer Effects Of GFT505 1/29/2014 9:33:40 AM
GENFIT Corp. (ALGFT) Release: GFT505: the DSMB Approves the Continuation of the Phase 2b Study in NASH 10/28/2013 8:47:37 AM
GENFIT Corp. (ALGFT) Release: GFT505 Reduces the Risk of Cardiovascular Events Through Its Action on Remnant Cholesterol 5/15/2013 10:22:08 AM
GENFIT Corp. (ALGFT): Conversions Into Shares of 30 Bonds OCA2012-2 4/29/2013 10:03:30 AM
GENFIT Corp. (ALGFT) Release: TGFTX1 Program: Successful Identification of Proprietary ROR?t Ligands for the Treatment of Auto-Immune Diseases 3/13/2013 12:43:06 PM
GENFIT Corp. (ALGFT) Release: First Nash Patients Treated With GFT505 in the U.S.A. and in Europe 11/20/2012 2:46:53 PM
GENFIT Corp. (ALGFT) to Participate at the 5th Annual European Life Sciences CEO Forum in Zurich on March 6th - 7th, 2012 2/29/2012 11:25:39 AM
12345
//-->